Floatz logo

Therapeutic Asset Ratings

6,371 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Plasmablastic Lymphoma
National Cancer Institute (NCI)P2BB (65)
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Juvenile Myelomonocytic Leukemia
Diane GeorgeP2BB (65)
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Thalassemia
National Heart, Lung, and Blood Institute (NHLBI)P2BB (65)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Nonpapillary Renal Cell Carcinoma
Regeneron PharmaceuticalsP2BB (65)
Ipilimumab
Cancer
7 Hills Pharma, LLCP2BB (65)
Ipilimumab
Metastatic Prostate Carcinoma
Andrew J. Armstrong, MDP2BB (65)
Ipilimumab
Ocular Melanoma
University of Michigan Rogel Cancer CenterP2BB (65)
Ipilimumab
Osteosarcoma
Children's National Research InstituteP2BB (65)
Ipilimumab
Rhabdomyosarcoma
Children's National Research InstituteP2BB (65)
Ipilimumab
Triple-Negative Breast Carcinoma
Emory UniversityP2BB (65)
MOGAMULIZUMAB
Mycosis Fungoides
Virogen Biotechnology Inc.P2BB (65)
Nivolumab
Ependymoma
University of FloridaP2BB (65)
Nivolumab
Hematopoietic And Lymphoid Cell Neoplasm
M.D. Anderson Cancer CenterP2BB (65)
Nivolumab
Intrahepatic Cholangiocarcinoma
Virogin Biotech Canada LtdP2BB (65)
Nivolumab
Malignant Pancreatic Neoplasm
Mayo ClinicP2BB (65)
Nivolumab
Primary Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityP2BB (65)
Nivolumab
Mantle Cell Lymphoma
University of WashingtonP2BB (65)
Nivolumab
Marginal Zone Lymphoma
University of WashingtonP2BB (65)
Nivolumab
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
M.D. Anderson Cancer CenterP2BB (65)
Nivolumab
Refractory Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityP2BB (65)
Nivolumab
Refractory Chronic Lymphocytic Leukemia
M.D. Anderson Cancer CenterP2BB (65)
Obinutuzumab
Richter Syndrome
Christine RyanP2BB (65)
Pembrolizumab
Acral Lentiginous Melanoma
Yonsei UniversityP2BB (65)
Pembrolizumab
Breast Adenocarcinoma
GenmabP2BB (65)
Pembrolizumab
Locally Advanced Malignant Solid Neoplasm
Mayo ClinicP2BB (65)
Showing 401 to 425 of 6,371 assets
PreviousPage 17 of 255Next